Spectrum Pharmaceuticals Enters Into License and Asset Purchase Agreement with Mundipharma

Advised Spectrum Pharmaceuticals Cayman, L.P., a wholly-owned subsidiary of Stradling client Spectrum Pharmaceuticals, Inc., on a license and asset purchase agreement with Mundipharma International Corporation Limited regarding the exclusive commercialization rights to ZEVALIN in Asia, excluding India and Greater China, Australia/New Zealand, Africa, the Middle East, and Latin America (including the Caribbean). Pursuant to the terms of the transaction, Spectrum Pharmaceuticals Cayman will receive $20 million, comprised of an upfront payment of $15 million plus $5 million in profits on the initial ZEVALIN supply.

Spectrum Pharmaceuticals is a biotechnology company with fully integrated commercial and drug development operations, with a primary focus on oncology and hematology.